Breast cancer and pregnancy: Why special considerations prior to treatment are needed in multidisciplinary care

Mingdi Zhang¹, Jing Zhou²,³,⁴, Ling Wang²,³,⁴,*

¹Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China; ²Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China; ³The Academy of Integrative Medicine of Fudan University, Shanghai, China; ⁴Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China.

SUMMARY Breast cancer diagnosed during pregnancy poses ethical and professional challenges. Clinical management of that condition should ensure the safety of both the mother and fetus. Clinical trials on breast cancer exclude pregnant women, so sufficient evidence with which to formulate guidelines for the management of these patients is lacking. Failing to undergo a breast examination during pregnancy, breast symptoms explained by physiological changes such as pregnancy, and unnecessary abortions after the diagnosis of breast cancer lead to worse outcomes for these patients. Multidisciplinary teams including breast surgeons, obstetricians, radiologists, pathologists, and anesthesiologists need to make an early diagnosis and comprehensively evaluate patients in different gestational weeks and with different stages of breast cancer in order to optimize outcomes.

Keywords breast cancer diagnosed during pregnancy, multidisciplinary teams, special considerations

1. Introduction

Breast cancer (BC) is the most common carcinoma in women worldwide (1-5), and about 7% of the cases were diagnosed before the age of 40 years (6,7). Cancer diagnosed during pregnancy is rare, with an incidence of 1 case per 1,000 deliveries (8). Breast cancer developing during pregnancy is rare, but it is the most common cancer affecting pregnancy. The incidence of breast cancer during pregnancy has been increasing (9). The rate of breast cancer among pregnant women age < 45 years has varied from 2.6% to 6.9% (10). By comparison, the rate in those age < 35 years has been 15.6% for all breast cancer cases (11).

BC diagnosed during pregnancy presents a complex challenge to the patient and to clinicians deciding how to manage the condition. Although the expectations are that pregnant patients with breast cancer will be treated as effectively as nonpregnant patients with breast cancer, the selection and delivery of standard therapies must be modified to balance maternal benefit and fetal risk. Assessment of the risks and benefits and a multidisciplinary team (MDT) approach at specialized centers are crucial to managing this group of patients (12-16).

The aims of the current article are to highlight the special considerations for pregnant women prior to treatment of breast cancer (Table 1) and to review the evidence for management of pregnant patients with breast cancer.

2. Tumor biology

Although the clinical characteristics of breast cancer in pregnant women are similar to those in nonpregnant women, diagnosis may be delayed due to the differential diagnoses of physiologic alterations related to pregnancy (17,18). Breast cancer is not caused by pregnancy but can occur coincidentally with pregnancy. Pregnancy may have a profound effect on the biology of breast cancer. Most of the breast cancer developing during pregnancy is invasive ductal carcinoma (19). Invasive lobular carcinoma develops far less frequently (20). Studies have reported that triple-negative breast cancer (TNBC) is more prevalent during pregnancy (21-23). The ultimate prognosis for breast cancer during pregnancy is a subject of debate. Although some studies have noted no significant differences in the prognosis for breast cancer during pregnancy or otherwise (24-26), a recent meta-analysis noted a poor prognosis for breast cancer in pregnant women (27). Compared to sporadic breast cancer, breast cancer that develops during pregnancy has a higher histologic grade, a more aggressive profile, is in a more advanced stage at...
diagnosis, is larger in size, has a higher frequency of nodal involvement, less frequently expresses estrogen receptors (ERs) and progesterone receptors (PRs), and is more likely to be inflammatory breast cancer (28).

The effects of pregnancy may alter certain patterns of gene expression in breast cancer cells compared to normal breast tissue (29,30). The aberrant expression of several oncogenes (MYC, SRC, and FOS), tumor suppressor genes (TP53, PTEN, and CAV1), apoptosis regulators (PDCD4, BCL2, and BIRC5), transcription regulators (JUN, KLF1, and SP110), genes involved in DNA repair mechanisms (Sig20, BRCA1, BRCA2, and FEN1), genes involved in cell proliferation (AURKA and MKI67), genes involved in the immune response (PD1 and PDL1), and genes involved in other significant biological processes (protein modification or internal cell motility) has been noted in breast cancer diagnosed during pregnancy (29).

3. Diagnosis and staging

Diagnostic tests to diagnose breast cancer during pregnancy per trimester are summarized in Figure 1.

During pregnancy, the diagnosis of breast cancer is often delayed about 1 to 13 months due to enlargement of the breasts, colostrum secretion, and other changes (31). Although 80% of palpable breast masses found during pregnancy are benign, a mass diagnosed for > 2 weeks should be taken seriously (32).

The workup of a suspicious breast mass proceeds similarly during pregnancy or otherwise, but the standard staging workup should be predicated on fetal safety. A careful physical examination for suspected breast cancer during pregnancy that includes the breasts and regional lymph nodes is essential. A point worth noting is that breast ultrasonography should be the first imaging technique used to assess a breast mass during pregnancy because of its safety and high level of sensitivity. Although breast ultrasonography is less sensitive due to a higher density of the breast during pregnancy, mammography with appropriate abdominal shielding should be useful at evaluating the extent of disease (33,34). Gadolinium can cross the placental barrier and is considered potentially teratogenic (35), so magnetic resonance imaging (MRI) without gadolinium contrast can be used to further evaluate the breast during pregnancy (33).

A histopathologic examination of core needle biopsy specimens obtained under local anesthesia is the preferred method of sampling any clinically suspicious breast mass during pregnancy or otherwise (13). Suspected metastatic lymph nodes should also be evaluated with ultrasound and fine needle aspiration biopsy for cytologic confirmation (36). Pathologists should be informed of the patient's pregnancy because the presence of hyperplastic cells could simulate atypia.
leading to an increase in false-positive results (37).

Systemic staging studies are recommended for advanced cancers. Staging studies on patients during pregnancy must be performed only if the treatment options are going to be adjusted. If necessary, staging tests should include chest radiography with abdominal shielding, liver ultrasonography, and/or noncontrast skeletal MRI. The ESMO guidelines point out that bone scans and positron emission tomography (PET) should be avoided during pregnancy (38). Although a few studies have indicated that fluorodeoxyglucose (18F-FDG) PET and PET/magnetic resonance imaging (MRI) involve a low dose of fetal radiation exposure, there is not enough evidence to support the use of PET for breast cancer staging during pregnancy (39,40). Contrast-enhanced CT should be avoided during pregnancy.

A radiologist needs to be a key member of the medical team in order to calculate the total dose and review the indications as well as their risk-benefit ratios (41).

4. Pregnancy monitoring

Pregnant women with breast cancer should always be considered a high-risk group. Therefore, more careful and continuous monitoring with morphometric ultrasonography and umbilical artery Doppler assessment during gestation is mandatory. Calculation of gestational age and expected date of delivery are significant, which has an impact on breast cancer treatment planning (42,43). Allowing a pregnancy to reach full term (37 weeks) is strongly recommended. The gynecologist/obstetrician should be the part of the multidisciplinary team and determine the mode of delivery (44). Possible micrometastases in the placenta should be examined. In order to avoid hematological toxicity in the mother and fetus, the management of the last round of chemotherapy should be 3 weeks prior to the planned date of delivery (3). There is mounting evidence regarding the effects of breast cancer treatment on pregnancy outcomes. In general, therapy for breast cancer during pregnancy had no clear adverse effects on growth, cognitive function, and cardiac function in early childhood, suggesting that the diagnosis of cancer during pregnancy should not be an indication to abort the pregnancy. The only factor associated with a worse cognitive outcome was prematurity, irrespective of anticancer treatments (45).

5. Risk of anesthesia

Anesthesia considerations also include the safety of both the mother and the fetus. Changes in maternal anatomy and physiology during pregnancy increase the potential hazards for the mother and fetus undergoing anesthesia. Maternal changes include increased cardiac output (46), reduced functional residual capacity (47), dilation of the pyelocaliceal system (48), dilutional anemia (49), gastroesophageal reflux (50), and changes in glucose and adrenal metabolism (51). The risk of anesthesia-related morbidity and mortality during pregnancy mostly involves airway edema, restrictive lung physiology, and aspiration (52). A previous study suggested that adverse fetal outcomes after surgery may contribute to the mother's underlying condition rather than the effects of anesthesia (53). A point worth mentioning is that the patient should be positioned with a 15-30° left lateral tilt in order to reduce aortocaval compression and the incidence of supine hypotensive syndrome (54).

6. Treatment

Guidelines state that breast cancer during pregnancy should be treated in accordance with the management of breast tumors in non-pregnant women, including the local control of disease and the prevention of systemic metastases (38,39). To optimize the management of breast cancer during pregnancy, clinicopathological characteristics, gestational age at the diagnosis of breast cancer, expected date of delivery, and the patient's wishes should be considered. The goals of the multidisciplinary team are to cure the pregnant patient with breast cancer, to support the pregnancy, and to not harm the fetus (12).

6.1. Surgery during pregnancy

Surgery can be considered safe in all trimesters of pregnancy (38). The gestational age at diagnosis is an important factor in devising a surgical plan. Either a radical modified mastectomy (RMM) or breast-conserving surgery is a reasonable option for a pregnant woman with breast cancer. In the first trimester, however, radiotherapy following breast-conserving treatment may be delayed for the sake of fetal safety. Mastectomy should be recommended for patients who wish to continue the pregnancy (55). Breast-conserving surgery might be an option for early-stage BC in the second and third trimesters. Reconstructive surgery should be postponed until after birth, given concerns about normal changes in the breast after pregnancy and its unexpected cosmetic effects (56).

Although breast cancer during pregnancy has a high incidence of axillary metastases, sentinel lymph node biopsy should be suggested for patients with early-stage breast cancer. There is no level 1 evidence to support sentinel lymph node biopsy for breast cancer patients during pregnancy. The American Society of Clinical Oncology (ASCO) guidelines do not support this procedure (57). The National Comprehensive Cancer Network (NCCN) guidelines endorse the safety of this approach pursuant to the patient's wishes (57,58). Other guidelines advise sentinel lymph node biopsy when axillary ultrasound and a suspicious lymph node biopsy...
are negative (59). A sentinel lymph node biopsy should be performed using 99mTc-albumin nanocolloids (39). Blue dye and isosulfan blue should be avoided because of the risk of an allergic or anaphylactic maternal reaction, and methylene blue is contraindicated during the first trimester because it is teratogenic (60).

6.2. Systemic treatment during pregnancy

Generally, systemic treatments including chemotherapy, hormone therapy, targeted therapies, and immunotherapy are avoided in the first trimester because of the high risk of teratogenicity and abortion (Figure 2) (39,61,62). Available data on the teratogenic risks to pregnant women from all clinical trials are limited to case reports, animal studies, and studies with small samples. The major factors that should be taken into account before systemic therapy during pregnancy include physiologic changes during pregnancy, gestational age, placental passage, and the pharmacokinetic characteristics of the drug. Before any oncological treatment, a fetal ultrasound must be performed to exclude pre-existing abnormalities (60).

Anthracyclines are considered the treatment of choice because of the very low placental transfer (63). A previous study has reported that doxorubicin and epirubicin are not teratogenic (64), but another study reported that they tend to cause prematurity and low birth weight (65). Retrospective and prospective studies have examined different schedules and chemotherapy combinations, such as 3-week cycles of FAC (5-fluorouracil, doxorubicin, and cyclophosphamide), FEC (5-fluorouracil, epirubicin, and cyclophosphamide), AC (doxorubicin and cyclophosphamide), EC (epirubicin and cyclophosphamide), or weekly epirubicin as monotherapy (62,64-66). The AC and EC regimens are most often used to treat breast cancer during pregnancy. A retrospective cohort study indicated that dose-dense chemotherapy was safe in 10 pregnant women with breast cancer (67). However, a dose-dense schedule may not be recommended (68). Although chemotherapy has considered safe and well-tolerated, the multidisciplinary team must monitor fetal safety and maternal blood pressure. Moreover, chemotherapy should not be administered after 35 weeks of gestation in order to prevent hematological complications during delivery (69,70).

The use of trastuzumab throughout pregnancy is contraindicated due to the high risk of oligohydramnios and/or anhydramnios (39). The erbB2/neu gene is related to fetal organogenesis (71). A systematic review and meta-analysis of the safety of trastuzumab during pregnancy concluded that more adverse events occur during the second/third trimester than during the first trimester (72). No data are available on pertuzumab and T-DM1 administration in pregnant women, so both are contraindicated (73). A small molecule, lapatinib is presumed to be able to cross the placenta during all phases of pregnancy. The limited data on use of this tyrosine kinase inhibitor during pregnancy do not support its use in pregnant patients (74,75). Data on the use of CDK4 and CDK6 inhibitors throughout pregnancy are not yet available.

Endocrine therapy (tamoxifen and luteinizing hormone-releasing hormone analogues) is contraindicated for the treatment of breast cancer during pregnancy due to the high risk of birth defects (up to 17.6%) (76). Tamoxifen is teratogenic and increases the risk of breast cancer in offspring which has been verified in animal experiments (77,78). A systematic review has summarized major malformations (ambiguous genitalia, Pierre Robin sequence, and oculoauriculovertebral dysplasia) and minor malformations (preauricular skin tags and severe hypermetropia) in breast cancer patients exposed to tamoxifen during pregnancy (79). No data are available on human exposure to aromatase inhibitors during pregnancy, though there are data from animal models (80).

Radiation has dose- and gestational-week-dependent effects on the fetus (81). Due to its teratogenic effects, radiation therapy is not considered a safe treatment option (82). Radiotherapy could be performed in the first trimester and at the beginning of the second after a careful dose adjustment (exposure of 0.01 mGy is below the threshold dose) and proper abdominal shielding (83). The multidisciplinary team should balance the risks and benefits of administering radiotherapy, both for the mother and the fetus.

The PD-1/PD-L1 pathway is involved in immune

| System Treatment     | First trimester | Second trimester | Third trimester |
|----------------------|-----------------|------------------|-----------------|
| Chemotherapy         | Red             | Yellow           | Red             |
| Radiotherapy         | Red             | Yellow           | Red             |
| Endocrine therapy    | Red             | Yellow           | Red             |
| Targeted therapy     | Red             | Yellow           | Red             |
| Immunotherapy        | Red             | Yellow           | Red             |

Figure 2. Systemic treatment per trimester. Green: recommended; Yellow: only in selected cases; Red: contraindicated.
tolerance during pregnancy (84). In models involving
pregnant animals, anti-PD-1/PD-L1 treatment increased
the risk of miscarriages, premature delivery, and birth
mortality (85), so immunotherapy during pregnancy is
contraindicated.

7. Conclusion

The management of breast cancer during pregnancy is
a major ethical and professional challenge for both the
patient and the multidisciplinary treatment team. Due
to the special physiological stage that those patients are
in, some special considerations should be made. The
patient's medical history needs to be understood in detail,
the patient needs to be evaluated as comprehensively
as possible via limited additional examinations, and
the entire pregnancy should be monitored in order to
formulate a reasonable treatment plan, to ensure the
safety of the fetus and the mother, and to ensure the
effectiveness of cancer treatment.

Funding: This work was supported by grants for a
clinical research project from the Shanghai Municipal
Commission of Health (grant no. 20194Y0123 to MD
Zhang), for a project to foster clinical research from
the Obstetrics and Gynecology Hospital of Fudan
University (grant no. 20017 to MD Zhang), for an
innovative medical research project under the Scientiﬁc
and Technological Innovation Action Plan (grant no.
20Y11914500 to MD Zhang), for a 2018 Science
and Technology Project to Guide Medicine from the
Shanghai Municipal Commission for Science and
Technology (grant no.18401902200 to L Wang), for a
project under the Scientiﬁc and Technological Innovation
Action Plan of the Shanghai Natural Science Fund (grant
no. 20ZR1409100 to L Wang), for a project from the
Chinese Association of Integration of Traditional and
Western Medicine special foundation for Obstetrics and
Gynecology-PuZheng Pharmaceutical Foundation (grant
no. FCK-PZ-08 to L Wang).

Conflict of Interest: The authors have no conﬂicts of
interest to disclose.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer
statistics, 2021. CA Cancer J Clin. 2021; 71:7-33.
2. Soto-Trujillo D, Santos Aragon LN, Kimura Y. Pregnancy-
associated breast cancer: What radiologists must know.
Cureus. 2020; 12:e10343.
3. Bar-Joseph H, Peccatori FA, Goshen-Lago T, Cribiu FM,
Scarfone G, Miller I, Nemerovsky L, Levi M, Shalgi
R, Ben-Aharon I. Cancer during pregnancy: The role
of vascular toxicity in chemotherapy-induced placental
toxicity. Cancers (Basel). 2020; 12:1277.
4. Yang Z, Ji L, Jiang G, Liu R, Liu Z, Yang Y, Ma Q, Zhao
H. FL118, a novel camptothecin analogue, suppressed
migration and invasion of human breast cancer cells by
inhibiting epithelial-mesenchymal transition via the Wnt/
beta-catenin signaling pathway. Biosci Trends. 2018;
12:40-46.
5. Zhang N, Zhang Y, Lin J, Qiu X, Chen L, Pan X, Lu Y,
Zhang J, Wang Y, Li D, Wang L. Low-density lipoprotein
receptor deﬁciency impaired mice osteoblastogenesis in
vitro. Biosci Trends. 2018; 11:658-666.
6. Thomas A, Rhoads A, Suhl J, Conway KM, Hundley WG,
McNally LR, Oleson J, Melin SA, Lynch CF, Romitti PA.
Incidence and survival by human epidermal growth factor
receptor 2 status in young women with stage I-II breast
cancer: SEER, 2010-2016. Clin Breast Cancer. 2020;
20:e410-e422.
7. Ghiasvand R, Adami HO, Harirchi I, Akrami R,
Zendehdel K. Higher incidence of premenopausal breast
cancer in less developed countries; myth or truth? BMC
Cancer. 2014; 14:343.
8. Benoit L, Mir O, Vialard F, Berveiller P. Cancer
during pregnancy: A review of preclinical and clinical
transplacental transfer of anticancer agents. Cancers
(Basel). 2021; 13:1238.
9. Dur ES, Irfan S, Islam ZS, Sheikh L. Impact of pregnancy
on cancer survival: Experience at a tertiary care hospital.
Pak J Med Sci. 2021; 37:335-338.
10. Ruiz R, Herrero C, Strasser-Weippl K, Touya D, St
Louis J, Bukowski A, Goss PE. Epidemiology and
pathophysiology of pregnancy-associated breast cancer: A
review. Breast. 2017; 35:136-141.
11. Dodelzon K, Sturikov A, Reichman M, Cheng E, Lu
CM, Blackburn A, Reznik E, Kim J, Bose A, Thomas C,
Askin G, Arleo EK. Breast cancer in women under age
40: A decade of trend analysis at a single institution. Clin
Imaging. 2021; 78:165-170.
12. Poggio F, Tagliamento M, Pirrone C, Soldato D, Conte
B, Molinelli C, Cosso M, Fregatti P, Del Mastro L,
Lambertini M. Update on the management of breast
cancer during pregnancy. Cancers (Basel). 2020;
12:3616.
13. Paris I, Di Giorgio D, Carbognin L, et al. Pregnancy-
associated breast cancer: A multidisciplinary approach.
Clin Breast Cancer. 2021; 21:e120-e127.
14. Wu Q, Wang X, Wu F, Peng D, Wu G, Yang L, Yuan L.
Role of a multidisciplinary team (MDT) in the diagnosis,
treatment, and outcomes of inflammatory bowel disease:
A single Chinese center's experience. Biosci Trends.
2021; 15:171-179.
15. Zhang Z, Li Y, Li K, Zhai G, Dang X, Zhong C, Shi
Z, Zou R, Wang L, Wei D, Tang B, Ge J. Value of
multidisciplinary team (MDT) in minimally invasive
treatment of complex intrahepatic bile duct stones. Biosci
Trends. 2021; 15:161-170.
16. Qiu G, Xie K, Jin Z, Jiang C, Liu H, Wan H, Huang J. The
multidisciplinary management of hepatocellular carcinoma
with portal vein tumor thrombus. Biosci Trends. 2021;
15:148-154.
17. Al-Amri AM. Clinical presentation and causes of the
delayed diagnosis of breast cancer in patients with
pregnancy associated breast cancer. J Family Community
Med. 2015; 22:96-100.
18. Jahanbin B, Soleimani V. Histology of pregnancy-
associated breast cancer. Adv Exp Med Biol. 2020;
1252:81-86.
19. Schad A, Slostad J, Rao R. Gestational breast cancer:
Current challenges in staging and treatment of breast
cancer. BMJ Case Rep. 2020; 13:e225308.
20. Kim YG, Jeon YW, Ko BK, Sohn G, Kim EK, Moon

www.biosciencetrends.com
B1, Youn HJ, Kim HA, Korean Breast Cancer S. Clinopathologic characteristics of pregnancy-associated breast cancer: Results of analysis of a nationwide breast cancer registry database. J Breast Cancer. 2017; 20:264-269.

21. Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmedi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA, Tonetti DA. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. Springerplus. 2015; 4:710.

22. Zhang R, Liu X, Huang W, Shao B, Yan Y, Liang X, Ran R, Song G, Di L, Jiang H, Li H. Clinopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study. Asia Pac J Clin Oncol. 2021; 17:396-402.

23. Allouch S, Gupta I, Malik S, Al Farsi HA, Vranic S, Al Moustafa AE. Breast cancer during pregnancy: A marked propensity to triple-negative phenotype. Front Oncol. 2020; 10:580345.

24. Iqbal J, Amir E, Rochon PA, Giannakeas V, Sun P, Narod SA. Association of the timing of pregnancy with survival in women with breast cancer. JAMA Oncol. 2017; 3:659-665.

25. Ploquin A, Pistilli B, Tresch E, et al. 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. Eur J Cancer. 2018; 95:30-37.

26. Choi M, Han J, Yang BR, Jang MJ, Kim M, Kim TY, Im SA, Lee HB, Moon HG, Han W, Noh DY, Lee KH. Prognostic impact of pregnancy in Korean patients with breast cancer. Oncologist. 2019; 24:e1268-e1276.

27. Shao C, Yu Z, Xiao J, Hong F, Zhang Y, Jia H. Prognosis of pregnancy-associated breast cancer: A meta-analysis. BMC Cancer. 2020; 20:746.

28. Linares S, Alrammah T, Alghamdi HA, Moller MG. Inflammatory breast cancer in pregnancy and lactation. Adv Exp Med Biol. 2020; 1252:143-151.

29. Korakiti AM, Moutafi M, Zografos E, Dimopoulos MA, Zagouris F. The genomic profile of pregnancy-associated breast cancer: A systematic review. Front Oncol. 2020; 10:1773.

30. Gutierrez-Diez PJ, Gomez-Pilar J, Hornero R, Martinez-Rodriguez J, Lopez-Marcos MA, Russo J. The role of gene to gene interaction in the breast's genomic signature of pregnancy. Sci Rep. 2021; 11:2643.

31. Woo JC, Yu T, Hurc TC. Breast cancer in pregnancy: A literature review. Arch Surg. 2003; 138:91-98; discussion 99.

32. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Womens Health (Lond). 2009; 5:243-249.

33. Wang PL, Chong ST, Kielar AZ, Kelly AM, Knoepf UD, Mazza MB, Goodsett MM. Imaging of pregnant and lactating patients: Part 1, Evidence-based review and recommendations. AJR Am J Roentgenol. 2012; 198:778-784.

34. Mattsson S, Leide-Svegborn S, Andersson M. X-Ray and molecular imaging during pregnancy and breastfeeding—When should we be worried? Radiat Prot Dosimet. 2021; ncb041.

35. Kumar R, De Jesus O. Radiation effects on the fetus. In: StatPearls (Treasure Island (FL), 2021).

36. Bajpai J, Simha V, Shylasree TS, et al. Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India. Breast. 2021; 56:88-95.

37. Vinatier E, Merlot B, Poncelet E, Collinet P, Vinatier D. Breast cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2009; 147:9-14.

38. Peccatori FA, Azim HA, Jr., Orecchia R, Hoekstra HJ, Pavlidis N, Kesch V, Penteroudakis G, Group EGW. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:v160-170.

39. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: Adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015; 1;1145-1153.

40. Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR. J Nucl Med. 2015; 56:1218-1222.

41. Cubillo A, Morales S, Goni E, Matute F, Munoz JL, Perez-Diaz D, de Santiago J, Rodriguez-Lescure A. Multidisciplinary consensus on cancer management during pregnancy. Clin Transl Oncol. 2021; 23:1054-1066.

42. Dong Y, Wang L, Lu Y, Fu Z, Du Y, Wang L. Factors affecting mode of delivery in women of advanced maternal age. Biosci Trends. 2021; 15:61-63.

43. Li C, Zhang N, Zhou J, Leung W, Gober HJ, Huang Z, Pan X, Chen L, Guan L, Wang L. Variations in the antithyroid antibody titre during pregnancy and after delivery. Risk Manag Healthc Policy. 2021; 14:847-859.

44. Azim HA, Jr., Del Mastro L, Scarfone G, Peccatori FA. Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more. Breast. 2011; 20:1-6.

45. Amant F, Vandenhoute T, Verhecke M, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015; 373:1824-1834.

46. Ouzounian JG, Elkayam U. Physiologic changes during normal pregnancy and delivery. Cardiol Clin. 2012; 30:317-329.

47. Hirlme L, Lysenko L, Gerber H, Lesnik P, Baranowska A, Rachwalik M, Leszczyszn J, Strozecki L. Respiratory function in pregnant women. Adv Exp Med Biol. 2013; 788:153-160.

48. Ravindra GL, Madamangalam AS, Seetharamaiah S. Anaesthesia for non-obstetric surgery in obstetric patients. Indian J Anaesth. 2018; 62:710-716.

49. Sun D, McLeod A, Gandhi S, Malinowski AK, Shehata N. Anemia in pregnancy: A pragmatic approach. Obstet Gynecol Surv. 2017; 72:730-737.

50. Auton M, Duran Castillo MY, Garcia OFD. Perioperative management of pregnant women undergoing nonobstetric surgery. Cleve Clin J Med. 2020; 88:23-24.

51. Carlin A, Alfirevic Z. Physiological changes of pregnancy and monitoring. Best Pract Res Clin Obstet Gynaecol. 2008; 22:801-823.

52. Eskandari A, Alipour S. Aspects of anesthesia for breast surgery during pregnancy. Adv Exp Med Biol. 2020; 1252:161:1178-1185.

53. Moaveni DM, Birnbach DJ, Ramasinghe JS, Yasin SY. Fetal assessment for anesthesiologists: Are you evaluating
the other patient? Anesth Analg. 2013; 116:1278-1292.
55. Toesca A, Gentilini O, Peccatori F, Azim HA Jr, Amant F. Locoregional treatment of breast cancer during pregnancy. Gynecol Surg. 2014; 11:279-284.
56. Yi Ji, Kim KT. Gynecologic malignancy in pregnancy. Obstet Gynecol Sci. 2013; 56:289-300.
57. Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35:561-564.
58. Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18:452-478.
59. Giammarile F, Alazraki N, Aarsvold JN, Audisio RA, Glass E, Grant SF, Kumikowska J, Leidenius M, Moncayo VM, Uren RF, Oyen WJ, Valdes Olmos RA, Vidal Sicart S. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013; 40:1932-1947.
60. Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012; 379:570-579.
61. Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, Rosa R, Grazia di C. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol. 2005; 73:634-637.
62. Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: An 18-year experience from five London teaching hospitals. J Clin Oncol. 2005; 23:4192-4197.
63. Framarino-Dei-Malatesta M, Sammartino P, Napoli A. Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus? BMC Cancer. 2017; 17.777.
64. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: An observational study. Lancet Oncol. 2012; 13:887-896.
65. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: Maternal and fetal outcomes. Cancer J. 2010; 16:76-82.
66. Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, Yang W, Perkins G, Hortobagyi GN, Theriault RL. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006; 107:1219-1226.
67. Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol. 2012; 120:1267-1272.
68. Peccatori FA, Lamberti M, Scarfone G, Del Pup L, Codacci-Pisanelli G. Biology, staging, and treatment of breast cancer during pregnancy: Reassessing the evidences. Cancer Biol Med. 2018; 15:6-13.
69. Alfassi A, Ben-Aharon I. Breast cancer during pregnancy: Current paradigms, paths to explore. Cancers (Basel). 2019; 11:1669.
70. Berveiller P, Mir O, Degrelle SA, Tsatsaris V, Selleret L, Guibourdenc J, Evaïn-Brion D, Fournier T, Gil S. Chemotherapy in pregnancy: Exploratory study of the effects of paclitaxel on the expression of placental drug transporters. Invest New Drugs. 2019; 37:1075-1085.
71. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995; 378:394-398.
72. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulou MA, Bartsch R. Trastuzumab administration during pregnancy: A systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 137:349-357.
73. Shachar SS, Gallagher K, McGuire K, Zagar TM, Faso A, Muss HB, Sweeting R, Anders CK. Multidisciplinary management of breast cancer during pregnancy. Oncologist. 2017; 22:324-334.
74. Kelly H, Graham M, Humes E, Dorflinger LJ, Boggess KA, O’Neil BH, Harris J, Spector NL, Dees EC. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer. 2006; 7:339-341.
75. Lambertini M, Martel S, Campbell C, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019; 125:307-316.
76. Al Jishi T, Sergi C. Current perspective of diethylstilbestrol (DES) exposure in mothers and offspring. Reprod Toxicol. 2017; 71:71-77.
77. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast. 2004; 13:446-451.
78. Halakivi-Clarke L, Che O, Onojafe I, Liao DJ, Clarke R. Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring. Clin Cancer Res. 2000; 6:305-308.
79. Buonomo B, Brunello A, Noli S, Miglietta L, Del Mastro L, Lamberti M, Peccatori FA. Tamoxifen exposure during pregnancy: A systematic review and three more cases. Breast Care (Basel). 2020; 15:148-156.
80. Tiboni GM. Aromatase inhibitors and teratogenesis. Fertil Steril. 2004; 81:1158-1159; author reply 1159.
81. Keyser EA, Staat BC, Fausett MB, Shields AD. Pregnancy-associated breast cancer. Rev Obstet Gynecol. 2012; 5:94-99.
82. Behrman RH, Homer MJ, Yang WT, Whitman GJ. Mammography and fetal dose. Radiology. 2007; 243:605; author reply 605-606.
83. Greskovitch JF, Jr., Macklis RM. Radiation therapy in pregnancy: Risk calculation and risk minimization. Semin Oncol. 2000; 27:633-645.
84. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine. 2003; 21:3352-3357.
85. Hepner A, Negri D, Hase EA, Exman P, Testa L, Trinconi AF, Filassi JR, Francisco RPV, Zugai M, O’Connor TL, Martin MG. Cancer during pregnancy: The oncologist overview. World J Oncol. 2019; 10:28-34.

Received May 11, 2021; Revised August 30, 2021; Accepted September 17, 2021.

*Address correspondence to: Dr. Wangling@fudan.edu.cn.

Released online in J-STAGE as advance publication September 23, 2021.

www.bioscientetrends.com